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It is increasingly recognized that interventions for dementia must shift towards prevention to obtain 
maximal efficacy and any significant degree of disease modification. Nutritional supplementation with single 
agents has shown varied results, suggesting the need for combinatorial intervention.  
 
Methods 
We conducted a 3-month, randomized, multi-site, phase II study in which 141 individuals diagnosed with 
Alzheimer’s disease (AD) and 34 individuals with Mild Cognitive Impairment received a nutraceutical 
formulation (NF; folate, alpha-tocopherol, B12, S-adenosyl methioinine, N-acetyl cysteine, acetyl-L-carnitine) or 
indistinguishable placebo under double-blind conditions, followed by an open-label extension in which all 
individuals received NF for a total of 1yr.  An additional 38 individuals with AD received NF under open-label 
conditions from baseline for 1yr. The primary outcome was defined as cognitive performance. Secondary 
outcomes were defined as behavioral and psychological symptoms of dementia and activities of daily living.  
 
Results 
Participants radomized to NF improved statistically within 3 months in cognitive performance as 
ascertained by Clox-1 and the Dementia Rating Scale, and their caregivers reported improvement in 
Neuropsychiatric Inventory.   Participants receiving NF either continued to improve or maintained their baseline 
performance during open-label extensions.   Participants randomized to placebo did not improve, but during 
open-label extensions displayed similar improvement within 3 months to that of participants initially randomized 
to NF.  Caregivers reported no change in Activities of Daily Living for either cohort. 
 
Conclusions 
These findings confirm and extend prior phase I studies in which NF improved or maintained cognitive 
performance and behavioral symptoms for individuals with AD, and improved cognitive performance for 
community-dwelling individuals without dementia. 
 
In published studies with transgenic mice NF reduced PS-1 expression, beta and gamma secretase 
activity, Abeta deposits, phospho-tau, homocysteine and oxidative damage, and increased acetylcholine and 
glutathione.  This comprehensive impact of NF on AD-related neuropathology supports the possibility that NF 
may harbor disease-modifying properties. 
